TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition.
Torres P. et al, (2024), Acta Neuropathol, 148
Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression.
González-Martínez I. et al, (2023), Mol Ther Nucleic Acids, 34
Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.
Stoodley J. et al, (2023), Int J Mol Sci, 24
A modular RNA delivery system comprising spherical nucleic acids built on endosome-escaping polymeric nanoparticles
Garcia-Guerra A. et al, (2023), Nanoscale Advances
Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.
Stoodley J. et al, (2023), Methods Mol Biol, 2587, 209 - 237
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model.
Overby SJ. et al, (2022), Mol Ther Nucleic Acids, 27, 1146 - 1155
The Emerging Potential of Advanced Targeted Mass Spectrometry to Become a Routine Tool for Protein Quantification in Biomedical Research.
Varela MA. and Schmidt A., (2022), Chimia (Aarau), 76, 81 - 89
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.
Cerro-Herreros E. et al, (2021), Mol Ther Nucleic Acids, 26, 174 - 191
Comparable Outcomes of Matched Sibling Donor and Matched Unrelated Donor Stem Cell Transplantation in Children With Acute Leukemia in Argentina.
Gómez SM. et al, (2021), J Pediatr Hematol Oncol
Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S. et al, (2020), Mol Ther, 28, 2527 - 2539
A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN.
Rademacher S. et al, (2020), Cells, 9
Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion.
Sathyaprakash C. et al, (2020), Methods Mol Biol, 2176, 185 - 208
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.
Klein AF. et al, (2019), J Clin Invest
Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
Holland A. et al, (2018), NEUROMUSCULAR DISORDERS, 28, S8 - S9
Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7.
Curtis HJ. et al, (2017), Nucleic Acids Res, 45, 7870 - 7885